Abeona Therapeutics (ABEO) Short term Debt (2010 - 2026)

Abeona Therapeutics' Short term Debt history runs 14 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 63.64% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 63.64% increase from a year earlier, with the FY2025 full-year figure at $12.2 million, up 106.24% from the prior year.
• Short term Debt improved to $13.3 million in Q1 2026 per ABEO's latest filing, from $12.2 million in the prior quarter.
• Across five years, Short term Debt topped out at $13.3 million in Q1 2026 and bottomed at $2.2 million in Q2 2024.
• The 5-year median for Short term Debt is $4.9 million (2022), against an average of $6.5 million.
• Biggest YoY gain for Short term Debt was 174.06% in 2022; the steepest drop was 85.7% in 2022.
• Year by year, Short term Debt stood at $4.9 million in 2022, then declined by 6.93% to $4.6 million in 2023, then climbed by 29.39% to $5.9 million in 2024, then surged by 106.24% to $12.2 million in 2025, then advanced by 9.09% to $13.3 million in 2026.
• Per Business Quant, the three latest ABEO Short term Debt figures stand at $13.3 million (Q1 2026), $12.2 million (Q4 2025), and $8.9 million (Q3 2025).